Genetics and poor healthcare contribute to Black men's prostate cancer disparities. Unequal care, not biology, is the root ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...

A review of 22 trials led the American Society of Clinical Oncology (ASCO) to issue updates to its mCRPC systemic therapy ...

Guidelines created by a multi-disciplinary panel of specialists ... they called out the need for routine genetic testing of patients with advanced prostate cancer and emphatically called out ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

A U.S. FDA panel of independent experts beat ... for individuals with castration-resistant prostate cancer that have the HRR gene mutation. Pfizer submitted an sNDA to have the drug used with ...

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

Using a custom genotyping panel, polygenic risk scores were calculated based on 130 prostate cancer–associated single-nucleotide polymorphisms (SNPs). Those in the top 10% of genetic risk (≥ ...

A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor ...

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic ...

Standard medical practice is to not test men who have a life expectancy of less than 10 years for prostate cancer.